[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Vanda Pharmaceuticals: The Tradipitant Timeline Matters More Than the Fanapt Numbers

Vanda Pharmaceuticals Inc. (VNDA) reports second-quarter 2026 earnings after the close on August 5, 2026, with analysts expecting another quarterly loss as the company navigates its transition following recent product launches and guidance revisions. The central question is whether management can demonstrate progress toward profitability amid elevated cash burn and mixed execution on its growth initiatives. With the stock down sharply year-to-date and technical indicators flashing warning signals, this report will test investor confidence in the company's turnaround strategy.

Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for central nervous system disorders, with its primary revenue driver...

Fundamentals

See More
  • Market Capitalization, $K 320,520
  • Shares Outstanding, K 60,135
  • Annual Sales, $ 216,110 K
  • Annual Income, $ -220,470 K
  • EBIT $ -153 M
  • EBITDA $ -143 M
  • 60-Month Beta 0.64
  • Price/Sales 1.46
  • Price/Cash Flow N/A
  • Price/Book 1.12

Options Overview Details

View History
  • Implied Volatility 103.07% (+17.21%)
  • Historical Volatility 40.18%
  • IV Percentile 71%
  • IV Rank 24.71%
  • IV High 332.52% on 11/14/25
  • IV Low 27.75% on 09/04/25
  • Expected Move (DTE 15) 0.51 (10.02%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 293
  • Volume Avg (30-Day) 287
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 11,402
  • Open Int (30-Day) 10,183
  • Expected Range 4.58 to 5.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 2
  • High Estimate $-0.49
  • Low Estimate $-0.52
  • Prior Year $-0.46
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.93 +3.14%
on 07/29/26
6.61 -23.05%
on 07/08/26
-1.12 (-18.04%)
since 07/02/26
3-Month
4.93 +3.14%
on 07/29/26
7.74 -34.20%
on 05/06/26
-2.30 (-31.12%)
since 05/05/26
52-Week
4.14 +22.95%
on 08/07/25
9.94 -48.79%
on 03/10/26
+0.88 (+20.90%)
since 08/05/25

Most Recent Stories

More News
Vanda: Q2 Earnings Snapshot

Vanda: Q2 Earnings Snapshot

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

WASHINGTON , Aug. 5, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026. 

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals: The Tradipitant Timeline Matters More Than the Fanapt Numbers

Barchart Research What to Expect from VNDA Earnings VNDA Generated August 4, 2026 Current Price $5.33 EPS Estimate $$-0.50 Consensus Rating Moderate Buy Average Move 8.65% Vanda Pharmaceuticals: The Tradipitant...

VNDA : 5.09 (-4.50%)
Vanda's Pipeline Momentum Collides With a Shrinking Commercial Base

Barchart Research What to Expect from VNDA Earnings VNDA Generated July 29, 2026 Current Price $5.05 EPS Estimate $$-0.50 Consensus Rating Moderate Buy Average Move 8.65% Vanda's Pipeline Momentum Collides...

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

Conference Call and Webcast to Follow

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

WASHINGTON , July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA)...

VNDA : 5.09 (-4.50%)
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

WASHINGTON , July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention...

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

WASHINGTON , July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind,...

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

WASHINGTON , July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation...

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

WASHINGTON , May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation...

VNDA : 5.09 (-4.50%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 5.69
2nd Resistance Point 5.55
1st Resistance Point 5.32
Last Price 5.09
1st Support Level 4.95
2nd Support Level 4.81
3rd Support Level 4.58

See More

52-Week High 9.94
Fibonacci 61.8% 7.72
Fibonacci 50% 7.04
Fibonacci 38.2% 6.36
Last Price 5.09
52-Week Low 4.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.